Sydney, Jan 10, 2026, 16:52 AEDT — Market closed
- CSL slipped 0.09% to close at A$174.29 on Friday, following a 2.62% gain the previous session
- A filing revealed that 34,261 unquoted employee rights expired on Jan. 7
- CSL’s half-year results and interim dividend announcement on Feb. 11 will be the next key catalyst
CSL Limited shares slipped 0.09% to close at A$174.29 on Friday, following a 2.62% gain the previous day. This month, the stock has fluctuated between A$168.29 and A$175.60. (Investing)
This matters since CSL has been a tricky stock, sliding sharply and now trailing the broader ASX 200 by roughly 44 percentage points over the last year, per Market Index data. (Market Index)
CSL’s financial calendar pins down a key date: the company will release its half-year results and declare an interim dividend on Feb. 11. Shares are due to go ex-dividend on March 10, meaning from that day, they’ll trade without entitlement to the payout. (CSL Limited)
A company filing on Friday revealed 34,261 unquoted rights lapsed on Jan. 7, with CSL attributing the lapse to the processing of “December 2025 leavers.”
CSL jumped 2.62% to A$174.45 Thursday, powering the ASX 200 higher even as much of Asia saw softer trade. Sigma Healthcare and Pro Medicus also gained, according to news.com.au. eToro market analyst Zavier Wong described the wider sell-off as “a breather,” noting that CSL is drawing contrarian attention following a disappointing 2025.
CSL is still dealing with fallout from its October reset, when it slashed full-year revenue growth guidance to 2%-3% and cut expected NPATA growth to 4%-7% on a constant-currency basis. The company also pushed back the planned spin-off of its Seqirus vaccines unit. CEO Paul McKenzie pointed to “a greater decline” in U.S. flu vaccination rates than anticipated. (Reuters)
The company had previously announced job cuts and a share buyback program, kicking off with A$750 million in fiscal 2026, all part of a wider restructuring effort. (Reuters)
That said, the upcoming report could swing either way. A cautious update on plasma collections—the blood plasma CSL sources from donors to produce therapies—or vaccine demand might reignite concerns over earnings momentum. Meanwhile, currency fluctuations could impact reported profits.
Macro events remain in focus, with U.S. December consumer price data dropping Tuesday and Australia’s December CPI scheduled for Jan. 28. Both could move yields and the Australian dollar.
